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ABSTRACT
Objective clinical responses to anticancer treatments often do not translate into substantial improvements in
overall survival. Recent data suggesting many cancers arise from rare self-renewing cells (cancer stem cells)
that are biologically distinct from their more numerous differentiated progeny may explain this paradox.
Current anticancer therapies have been developed to target the bulk of the tumor mass (ie, the differentiated
cancer cells). Although treatments directed against the bulk of the cancer may produce dramatic responses,
they are unlikely to result in long-term remissions if the rare cancer stem cells are also not targeted. Better
understanding the biology of cancer stem cells and re-examining our preclinical and clinical drug development
paradigms to include the cancer stem cell concept have the potential to revolutionize the treatment ofmany cancers.
© 2007 American Society for Blood and Marrow Transplantation
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tISTORICAL PERSPECTIVE
It has been clear since at least the 1970s that only
minority of cells from most hematologic malignan-
ies and solid tumors are clonogenic in vitro and in
ivo [1,2]. Investigators called these rare clonogenic
ells “tumor stem cells” [1,2]. However, this low clo-
ogenic potential could represent proliferative capac-
ty exclusively restricted to a small subset of cancer
ells or alternatively all the cells within a cancer re-
aining the capacity to proliferate but only at a low
ate. Insufﬁcient tools available at the time precluded
nvestigators from distinguishing which of these 2 pos-
ibilities explained the low clonogenicity of most cancers.
Fialkow and his colleagues [3] ﬁrst suggested that
ML arose from a transformed hematopoietic stem
ell nearly 40 yr ago, when they showed that granu-
ocytes and RBCs from patients with CML had a
ommon cell of origin. The stem cell origin of CML
as conﬁrmed nearly 15 yr ago when several groups,
sing characteristics known to deﬁne normal HSC,
dentiﬁed and isolated CML stem cells capable of
xpansion ex vivo [4]. Dick and colleagues extended
hese observations 10 yr ago, showing that primitive
ematopoietic stem cells puriﬁed from patients with
ML [5] and CML [6] would generate leukemia in
ivo when injected into NOD/SCID mice. More re-
ently, cancer stem cells that are biologically distinct
rom the differentiated cells that make up the bulk of she tumor have also been found in myelodysplastic
yndromes [7], breast cancer [8], multiple myeloma
9], brain cancer [10,11], and lung cancer [12]. How-
ver, the biologic and clinical relevance of cancer stem
ells remains unclear.
ARADOX OF RESPONSE AND SURVIVAL
A cardinal principle of cancer therapeutics has
een that evidence of a clinical response will translate
nto improved survival. The major advantage of using
linical response as the primary endpoint of therapeu-
ic trials is that it is measurable over weeks to months,
llowing the stepwise process of drug development to
ccur more rapidly and efﬁciently. In contrast, dem-
nstrating a survival beneﬁt adds signiﬁcant complex-
ty to clinical trial design, usually requiring the accrual
f large patient numbers and long follow-up to pro-
ide statistical signiﬁcance.
Although clinical responses can clearly decrease
ide effects and improve quality of life, there is sur-
risingly little evidence that disease response is an
ppropriate surrogate for survival [13]. There are nu-
erous examples in which response does not predict
or an improved survival. Patients with indolent lym-
homa who achieved a CR with conventional-dose
herapies in the pre-rituximab era did not show a
urvival advantage over similar patients treated with a
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R. J. Jones and W. Matsui48watch and wait” approach [14]. In multiple myeloma,
either the magnitude nor the kinetics of clinical re-
ponse had an effect on survival [15]. Even the most
ntensive therapy for myeloma, blood transplantation
r BMT [16,17], provided no overall survival advan-
age in a recently published national intergroup trial
18] or a recent meta-analysis [19]. Similarly, signiﬁ-
ant clinical responses in pancreatic cancer [20] and
rostate cancer [21] have not translated into survival
eneﬁts. Further, despite new treatments that cur-
ently produce CRs in most women with ovarian car-
inoma, cures are rare [22].
ANCER STEM CELLS AND CANCER THERAPEUTICS:
HE DANDELION PHENOMENON
Emerging data with 1 of the most successful new
nticancer agents has helped shed light on this para-
ox that response and survival are not always linked.
matinib has replaced IFN- as the standard of care
or patients with newly diagnosed CML based on an
nterim analysis of a multicenter, randomized trial
howing higher response rates for imatinib [23]. With
p to 5 yr of follow-up, most of the cytogenetic CRs
o imatinib remain durable [24]. However, it now
ppears that imatinib may not be able to completely
radicate CML. Patients with CML who achieve the
est responses to imatinib (RT-PCR negativity for
CR-ABL transcripts) can relapse quickly when the
rug is discontinued [25-27] or even progress while
emaining on the drug [28].
BCR-ABL gene ampliﬁcation or mutations pre-
ent productive imatinib binding [29], and secondary
enetic mutations capable of driving BCR-ABL inde-
endent leukemic growth may also be present, even at
nitial diagnosis [30]. However, these genetic mecha-
isms of resistance are probably not responsible for
he persistent CML in most patients treated with
matinib. Several investigators have provided evidence
hat imatinib has differential effects on CML cells
epending on their state of differentiation: although
matinib is toxic to differentiated CML progenitors,
ML stem cells may be relatively or even completely
esistant to the drug [31-33]. The basis for the differ-
ntial activity of imatinib toward CML stem cells and
heir differentiated progeny is likely multifactorial
33]. CML stem cells share many biologic properties
ith their normal counterparts [4] that likely limit the
ffectiveness of therapeutic strategies targeting BCR-
BL signaling. Hematopoietic stem cells are largely
uiescent and normally express high levels of ATP-
inding cassette (ABC) transporters, such as the mul-
idrug resistance 1 gene [34] and ABCG2 [35]. Both
actors may limit the cellular uptake of imatinib,
hich is a substrate for the ABC transporters [36,37].
aybe most important, BCR-ABL appears to have mifferent effects on CML stem cells and their differ-
ntiated progeny [33]. The cellular expansion in CML
ccurs primarily in the differentiated progenitors,
ather than the in stem cell pool [4,38]. Moreover,
CR-ABL expression appears to be required for the
urvival of CML progenitors, but the same does not
ppear to be true for CML stem cells, where the
CR-ABL gene can be silent [4,39]. These data sug-
est that BCR-ABL may produce only subtle effects in
ML stem cells, and thus its inhibition may similarly
ave only minor consequences for these cells [33].
herefore, based on the longevity (possibly10 yr) of
heir normal counterparts, CML stem cells likely sur-
ive for years even if BCR-ABL activity is completely
nhibited [4]; eventually, because of intrinsic genomic
nstability, CML stem cells and their progeny may
evelop genetic resistance to imatinib.
The rapid responses induced in patients with
ML by imatinib [23] are likely a consequence of its
mpressive activity against differentiated CML pro-
enitors that make up the bulk of the leukemia. An
nability to cure CML [25-28] in the face of such
otent initial activity is consistent with CML stem cell
esistance to imatinib. This pattern of activity is anal-
gous to cutting a dandelion off at ground level; al-
hough this will eliminate the visible portion of the
eed, the unseen root also needs to be eliminated to
revent regrowth of the weed (Figure 1) [13,33,40].
onversely, the slow, but occasionally durable, re-
ponses seen in IFN-treated patients [41] is consistent
ith reports showing that the activity of IFN is di-
ected principally at the rare CML stem cells [33,42].
his treatment effect mimics attacking just the root of
he dandelion; although this has no immediately dis-
ernible effect on the weed, over time the weed will
ventually wither and die if its root has been elimi-
ated (Figure 1) [13,33,40].
The “dandelion phenomenon” also appears to ap-
ly to other cancers. Although multiple myeloma is
haracterized by neoplastic plasma cells, these cells
ppear to be terminally differentiated, like their nor-
al counterparts. The myeloma plasma cells that
orm the bulk of the tumor actually arise from a
inute population of less differentiated cancer stem
ells that resemble memory B cells and have the ability
o self-renew, differentiate, and maintain the disease
9]. It appears that most cancer stem cells arise from
ormal counterparts with stem cell features; although
ot stem cells in the classic sense, memory B cells
ould be considered “honorary” stem cells, ie, they are
ong-lived, self-renew, and differentiate into plasma
ells to maintain long-term immune memory. We
ound that the novel antimyeloma agents, bortezomib
nd lenalidomide, have little activity against myeloma
tem cells in vitro, despite being quite active against
he plasma cells [43]. Conversely, rituximab and ale-
tuzumab eliminated myeloma stem cells in vitro, but
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Cancer Stem Cells: From Bench to Bedside 49ad no activity against myeloma plasma cells that lack
he relevant target antigens (CD20 and CD52, respec-
ively). Although the activity of rituximab in multiple
yeloma has been disappointing [44], parameters typ-
cally used to follow clinical response in myeloma (ie,
onoclonal Ig level and percentage plasma cells in the
arrow) primarily measure the effect of therapies on
he terminally differentiated plasma cells. The long
urvival of the myeloma plasma cells could have ob-
cured activity against the myeloma stem cells respon-
ible for maintaining the disease. Perhaps a longer
uration of rituximab treatment could ultimately have
emonstrated clinical responses using traditional cri-
eria, by inhibiting new myeloma cell production for a
ufﬁcient period to allow terminally differentiated my-
loma plasma cells to undergo spontaneous apoptosis
Figure 1).
Gemtuzumab, an anti-CD33 antibody conjugated
o calicheamicin, has been approved to treat AML.
lthough the AML blasts usually express CD33, the
ML stem cells more closely resemble normal prim-
tive hematopoietic and may not express markers of
ore differentiated cells [5], including CD33 [45].
linical studies are also looking at monoclonal anti-
ody conjugates directed at B cell markers, such as
D19, in ALL [46,47]. CD19 is a marker of B cell
ifferentiation and not seen on many ALL stem cells
igure 1. “The dandelion phenomenon.” Most current anticancer
nticancer effects of such treatments are analogous to mowing d
differentiated cancer cells responsible for the bulk of the tumor), t
egrowth of the weeds. Equally problematic for drug developme
reatment effect mimics attacking just the roots of the dandelions; be
ells) will be seen, such potentially curative therapies could be prema
adet.48,49]. Thus, targeting markers such as CD33 in aML and CD19 in ALL is unlikely to improve the
urability of leukemia patients whose leukemia stem
ells do not also express these antigens.
ARGETING CANCER STEM CELLS
Currently, the search for novel anticancer thera-
ies is primarily focused on oncogenes that are speciﬁc
or (eg, BCR-ABL in CML) or overexpressed in (eg,
-myc or bcl-2) selected cancers. However, attacking
ancer-speciﬁc targets has met with variable success,
nd many of the most effective anticancer therapies,
uch as rituximab in lymphomas, high-dose cytotoxic
herapy, or the allogeneic graft-versus-tumor effect,
how limited or even no tumor selectivity. Targeting
cancer-speciﬁc pathway could fail for several rea-
ons. It is likely that many cancers have already ac-
uired multiple oncogenic mutations, even at initial
iagnosis, capable of driving tumor growth; in such
ases, targeting only 1 oncogene might be expected to
enerate limited activity. Further, as already dis-
ussed, even when the initiating oncogenic event is
argeted as with imatinib in CML, inherent properties
f stem cells may make the target inaccessible or no
onger relevant [33,40].
Properties shared with normal stem cells not only
es have been developed to target bulk tumor cell populations. The
ns; although this will eliminate the visible portion of the weeds
een roots (cancer stem cells) also need to be eliminated to prevent
therapies directed principally at the rare cancer stem cells. This
o immediately discernible effect on the weeds (differentiated cancer
bandoned. Lawnmower image reprinted with permission from Cubtherapi
andelio
he uns
nt are
cause n
turely appear to be responsible for cancer stem cell resistance
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R. J. Jones and W. Matsui50o many anticancer agents but may also lead to the
evelopment of novel therapies active across many
alignancies. Prospective targets shared with normal
tem cells may have particularly strong anticancer po-
ential because their conserved expression suggests a
ritical function retained by the cancer stem cells.
everal signaling pathways that are important for the
eneration and maintenance of normal stem cells dur-
ng embryonic development (eg, Notch, Wnt, and
edgehog [Hh]) [50] and/or postnatally (eg, telomer-
se [51] and growth factors) also appear to be impor-
ant for the growth of many cancers. Preliminary data
uggest that inhibition of these pathways, even when
hey are not mutated or overexpressed, may produce
otent antitumor activity across a range of malignan-
ies, possibly because of the key roles these pathways
lay in stem cell maintenance and growth.
Although toxicity from lack of tumor speciﬁcity is
n obvious concern for shared stem cell targets, there
re several potential differences between normal stem
ells and cancer stem cells that may provide a thera-
eutic ratio for shared targets. Normal stem cells have
ormal cell cycle checkpoints that are likely to protect
hem from cellular damage or crisis. The stage of
ifferentiation at which cancers arise may also provide
therapeutic ratio for approaches targeting cancer.
lthough many cancers may arise from tissue stem
ells, they may not be the most primitive tissue stem
ells as exempliﬁed by CML [4]. Accordingly, if a
herapy equally eliminated CML stem cells and their
ormal counterparts, the existence of more primitive
ormal stem cells should replenish the normal pro-
enitor pool [33].
Another example of a shared stem cell target po-
entially providing tumor selectivity is telomerase,
here differences between cancer stem cells and their
ormal counterparts in the interplay of telomere
ength and telomerase should provide a therapeutic
atio. Normal stem cells require telomerase to prevent
elomere shortening leading to replicative senescence.
owever, even in the absence of telomerase, normal
tem cells can maintain replicative capacity for some
eriod because of their relatively long telomeres. Ac-
ordingly, telomerase knockout mice show deﬁcits
nly after 4-6 generations [52]. In addition, the major
ause of death in dyskeratosis congenita, a congenital
isease that results from loss of function mutations in
elomerase components, is BM failure but this usually
oes not manifest until the second or third decade of
ife [53]. In contrast, uninterrupted telomerase activity
ay be absolutely required for the maintenance and
rowth of most malignancies to stabilize the short
elomeres that characterize cancer cells. Accordingly,
rossing telomerase knockout mice with INK4a/
54] or APCmin [55] mice predisposed to cancer signif-
cantly lowered the development of cancers in these
ice. Thus, the differential in telomere length betweenormal (long) and cancer (short) stem cells should pro-
ide telomerase inhibition differential sensitivity.
Because of the difﬁculty assessing the effects of
herapies on the rare cancer stem cells responsible for
elapse, the development of such approaches requires
ew clinical paradigms and methodologies [13]. We
elieve these new paradigms should rely heavily on
reclinical modeling, eliminate traditional measure-
ents of clinical response as trial endpoints, and use
ovel preclinical assays to evaluate the fate of cancer
tem cells. Preclinical studies should assess the effects
f therapies on cancer stem cell and differentiated
ancer cell populations. Using the correct preclinical
odels, it may be possible to develop a detailed un-
erstanding of the mechanisms of action of new treat-
ents and strategies for optimizing activity; this could
otentially allow a fully developed new approach to be
aken directly from the “bench to the bedside.” How-
ver, effective preclinical models for cancer stem cells
ay ease the task of clinical trial development but will
ot eliminate the need for new clinical paradigms. Eval-
ating the efﬁcacy of treatments against cancer stem cells
hould be possible by using these treatments after de-
ulking the differentiated cells that constitute the major-
ty of the tumor. In cancers where clinical debulking is
uccessful (ie, CRs are common but transient), studying
herapies after induction of remission should permit us-
ng duration of remission as a measurement of activity
gainst cancer stem cells. The fate of cancer stem cells
ould also be assessed as secondary laboratory endpoints
sing newly developed preclinical assays.
ONCLUSIONS AND FUTURE DIRECTIONS
Traditional response criteria measure tumor bulk
nd may not reﬂect changes in populations of rare
ancer stem cells [13]. Therapies directed against the
ulk of the cancer may produce dramatic responses
ut are unlikely to result in long-term remissions if
he rare cancer stem cells responsible for maintaining
he disease are also not targeted (Figure 1). Because
any currently active treatments have been developed
o target the differentiated cancer cells, they may have
ittle activity against the biologically distinct cancer
tem cells. Standard response parameters may not
nly potentially overestimate the effect of therapy on
he minute population of stem cells but may also
nderestimate it. As with IFN for CML and ritux-
mab in myeloma, therapy selectively directed at
ancer stem cells will not immediately eliminate the
ifferentiated tumor cells; such therapy therefore
ight be prematurely abandoned if clinical activity
s judged solely by standard response criteria that
eﬂect the effects of treatment on the bulk of the
ancer (Figure 1).Thus, improving the results of cancer therapy re-
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Cancer Stem Cells: From Bench to Bedside 51uires identiﬁcation and better understanding the bi-
logy of cancer stem cells and re-examining our pre-
linical and clinical drug development paradigms to
nclude the cancer stem cell concept. Studies identi-
ying and characterizing cancer stem cells from hema-
ologic malignancies have been greatly facilitated by a
omprehensive understanding of cell surface antigen
xpression throughout lymphohematopoietic differ-
ntiation. In contrast, little is known about the cell
urface phenotype associated with the growth and
evelopment of many nonlymphohematopoietic tis-
ues. However, shared stem cell properties may not
nly be important causes of drug resistance and im-
ortant targets for novel anticancer therapies but may
lso aid in identiﬁcation of cancer stem cells. Active
ellular efﬂux of the DNA binding dye Hoechst 33342
y ABC membrane transporters, especially ABCG2/
CRP, is at least partly responsible for the Hoechst
side population” that is characteristic of stem cells
rom many tissues [56]. Aldehyde dehydrogenase
ALDH), speciﬁcally the ALDH1 family, mediates the
ynthesis of intracellular all-trans-retinoic acid that is
equired for the growth of normal stem cells in the
ematopoietic system and other tissues [57]. The role
f ALDH is not limited to retinoic acid metabolism
ecause it is also involved in the detoxiﬁcation of a
ariety of compounds such as ethanol and the cyto-
oxic alkylator cyclophosphamide [57]. Similar to
oechst side population, high expression of ALDH
ppears to be a marker for stem cells from many
issues [58,59], and methodology to isolate viable cells
y ALDH activity using a ﬂuorescent labeled aldehyde
ubstrate (Aldeﬂuor) is currently available [58]. Data
rom several groups suggest that side population and
LDH may identify cancer stem cells from a variety
f malignancies [43,60] and may be particularly useful
n those malignancies where little is known about the
henotypes associated with the differentiation pro-
ram of the tissues of origin.
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